NWBO hasn't filed any applications and it will take them a long time to 'splain this dubious trial -- tossed out failed primary endpoint, replaced with new protocol, comparator, endpoints and SAP post hoc, confounding of PFS and naive OS, the post hoc data dredged recurrent OS endpoint they ginned up. Then there is the mystery FDA partial trial stop -- why did that occur and how do they deal with that in their application. So much 'splaining from NWBO who moves notoriously slow.
Market Data 
Markets 
AI
